C&CAUSES & WHAT WE KNOW
Causes & What We Know/November 16, 2026/3 min read

New Approach Uses Hydrogels to Teach the Immune System Tolerance in Type 1 Diabetes

Researchers developed injectable hydrogel depots that deliver insulin and immune-modulating molecules to create a tolerogenic environment, delaying diabetes onset in mouse models. This work suggests a new strategy for preventing Type 1 diabetes by restoring immune tolerance.

Research summaryPubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

causesautoimmunitygeneticsrisk

Key takeaways

  • Type 1 diabetes is caused by T cells attacking insulin-producing beta cells in the pancreas, leading to lifelong insulin dependence.
  • A new injectable hydrogel formulation delivers insulin antigen alongside low-dose IL-2 to create a 'tolerogenic niche' that recruits regulatory T cells.
  • In non-obese diabetic mice, this treatment delayed diabetes onset from a median of 20 weeks to more than 40 weeks.
  • The approach works by exposing the immune system to insulin antigen in a carefully controlled, tolerogenic environment rather than an inflammatory one.
  • This is early-stage research in mice; human clinical trials would be needed to determine safety and effectiveness in people with Type 1 diabetes.

Understanding Type 1 Diabetes as an Autoimmune Disease

Type 1 diabetes is a T-cell-mediated autoimmune disease, meaning the immune system mistakenly identifies and attacks the pancreas's insulin-producing beta cells. This destruction leads to insufficient insulin production and lifelong dependence on insulin therapy. People with Type 1 diabetes also face increased risk of serious complications without careful management.

Prevention strategies for Type 1 diabetes have focused on restoring immune tolerance—essentially teaching the immune system to recognize insulin-producing cells as 'self' rather than foreign threats. However, developing effective tolerogenic immunotherapies has proved challenging.

A New Strategy: Injectable Hydrogels and Tolerogenic Niches

Researchers have developed injectable hydrogel depot formulations designed to address key barriers in tolerogenic therapy. These hydrogels deliver two components: insulin autoantigen and low-dose interleukin-2 (IL-2), an immune signaling molecule. When injected under the skin, the hydrogels create what researchers call 'transient tolerogenic niches'—localized environments designed to promote immune tolerance rather than inflammation.

The hydrogel approach allows sustained, controlled release of both the antigen and the immunomodulator over time, which appears critical for achieving robust tolerance. Rather than exposing the immune system to these molecules all at once, the hydrogel depot releases them gradually, potentially giving immune tolerance mechanisms time to establish themselves.

How the Treatment Works: Recruiting Regulatory T Cells

When administered, the hydrogel depots recruit and expand regulatory T cells—immune cells that suppress inflammatory responses and promote tolerance—both within the hydrogel itself and in the draining lymph nodes. Regulatory T cells play a central role in preventing autoimmune attack. By creating an environment that expands these cells, the treatment appears to establish tolerance at multiple immune sites.

This tolerance response extended beyond the injection site, affecting immune cell populations in the spleen and pancreas, where the autoimmune attack on beta cells actually occurs. This systemic effect suggests the treatment can establish durable protection against the autoimmune process that drives Type 1 diabetes.

Promising Results in Mouse Models

In non-obese diabetic mice—a standard animal model for Type 1 diabetes research—the hydrogel treatment significantly delayed diabetes onset. Untreated mice typically developed diabetes at a median of 20 weeks. In contrast, mice receiving the hydrogel treatment had a median time to diabetes onset of more than 40 weeks, effectively doubling the time before disease emerged.

These results suggest that sustained co-exposure of autoantigen in the appropriate immune environment can promote durable tolerance for Type 1 diabetes prevention. However, it is important to note that this research is in early stages, conducted in animal models. Further development and human clinical trials would be necessary before this approach could be tested in people with Type 1 diabetes.

What This Means for Type 1 Diabetes Prevention

This research represents one approach to a fundamental challenge in Type 1 diabetes: how to restore immune tolerance before or early in the autoimmune process. The hydrogel strategy addresses several technical hurdles that have limited previous tolerogenic therapies, particularly the challenge of delivering antigens and immunomodulators in a controlled, spatiotemporal manner.

While results in mice are encouraging, significant work remains. Researchers will need to test whether similar approaches are safe and effective in people, particularly in those at high risk of developing Type 1 diabetes. The ultimate goal is a preventive strategy that could stop autoimmune attack before symptoms appear, but much additional research is needed to translate these findings from the laboratory to clinical practice.

Evidence label

Source: Advanced science (Weinheim, Baden-Wurttemberg, Germany). Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

From Type1Cure

Read more of our own writing in Stories

More evidence-labeled coverage across the Type1Cure library.